Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Orthofix Medical (OFIX) over the last 16 years, with Q3 2025 value amounting to -$9.9 million.

  • Orthofix Medical's Cash from Investing Activities fell 6878.2% to -$9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.9 million, marking a year-over-year increase of 4008.87%. This contributed to the annual value of -$27.6 million for FY2024, which is 1675.47% up from last year.
  • Orthofix Medical's Cash from Investing Activities amounted to -$9.9 million in Q3 2025, which was down 6878.2% from -$7.1 million recorded in Q2 2025.
  • In the past 5 years, Orthofix Medical's Cash from Investing Activities ranged from a high of $17.1 million in Q1 2023 and a low of -$22.3 million during Q3 2023
  • In the last 5 years, Orthofix Medical's Cash from Investing Activities had a median value of -$6.7 million in 2025 and averaged -$6.9 million.
  • Over the last 5 years, Orthofix Medical's Cash from Investing Activities had its largest YoY gain of 40146.46% in 2023, and its largest YoY loss of 30824.05% in 2023.
  • Over the past 5 years, Orthofix Medical's Cash from Investing Activities (Quarter) stood at -$9.0 million in 2021, then skyrocketed by 34.31% to -$5.9 million in 2022, then crashed by 155.14% to -$15.1 million in 2023, then soared by 92.46% to -$1.1 million in 2024, then plummeted by 771.72% to -$9.9 million in 2025.
  • Its Cash from Investing Activities stands at -$9.9 million for Q3 2025, versus -$7.1 million for Q2 2025 and -$6.7 million for Q1 2025.